Black Diamond Therapeutics, Inc. (BDTX) shareholders
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.47−0.05 (-3.29%)
Close on Nov 13, 2026Market cap $84.46MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.0%
35M of 57M shares
Institutional holders
96
25 new, 32 sold out
Net institutional buying
-3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BB Biotech AG Joint filing with Biotech Growth N.V. (15.10%) | 8,517,839 | 15.10% | 13G (passive) amendment | Dec 31, 2024 |
| Ali Behbahani Joint filing with New Enterprise Associates 16, L.P. (7.90%), NEA Partners 16, L.P. (7.90%) and 7 more | 4,546,947 | 8.10% | 13D (active) amendment | May 9, 2024 |
| Versant Ventures VI GP-GP, LLC Joint filing with Versant Ventures VI GP, L.P. (7.70%), Versant Venture Capital VI, L.P. (7.00%) | 4,328,883 | 7.70% | 13D (active) amendment | Aug 6, 2024 |
| T. Rowe Price Investment Management, Inc. | 4,028,202 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 3,838,590 | 6.70% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BDTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 4,448,757 | 7.74% | $8.23M | – | 0.52% |
| T. Rowe Price Investment Management, Inc. | 4,028,202 | 7.01% | $7.45M | −6,534,901 | 0.00% |
| BlackRock, Inc. | 3,917,088 | 6.82% | $7.25M | +2,810,248 | 0.00% |
| Acadian Asset Management LLC | 2,348,651 | 4.09% | $4.34M | – | 0.01% |
| Vanguard Capital Management LLC | 2,125,270 | 3.70% | $3.93M | +274,802 | 0.00% |
| Renaissance Technologies LLC | 1,962,394 | 3.42% | $3.63M | +318,647 | 0.00% |
| Defilade Capital Management, L.P. | 1,674,999 | 2.92% | $3.10M | New | 0.41% |
| Dimensional Fund Advisors LP | 1,365,384 | 2.38% | $2.53M | +63,720 | 0.00% |
| Geode Capital Management, LLC | 1,218,171 | 2.12% | $2.25M | +681,596 | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 1,092,885 | 1.90% | $2.02M | +34,488 | 0.00% |
| AWM Investment Company, Inc. | 1,000,000 | 1.74% | $1.85M | +475,000 | 0.16% |
| Marshall Wace, Llp | 896,602 | 1.56% | $1.66M | +60,336 | 0.00% |
| Bridgeway Capital Management, LLC | 791,434 | 1.38% | $1.46M | +67,957 | 0.03% |
| FMR LLC | 643,668 | 1.12% | $1.19M | +19,841 | 0.00% |
| Balyasny Asset Management L.P. | 542,172 | 0.94% | $1.00M | +31,361 | 0.00% |
| State Street Corp | 525,013 | 0.91% | $971.27K | +311,500 | 0.00% |
| Bank Of America Corp /De/ | 413,516 | 0.72% | $765.00K | +299,373 | 0.00% |
| Vanguard Portfolio Management LLC | 407,074 | 0.71% | $753.09K | +313,894 | 0.00% |
| Northern Trust Corp | 365,394 | 0.64% | $675.98K | −99,314 | 0.00% |
| Bank of New York Mellon Corp | 318,763 | 0.55% | $589.71K | +129,615 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 35M | 61.0% | 25 / 35 | 24 / 32 | 9M | 13M |
| Q1 2026 | 104 | 39M | 67.0% | 23 / 30 | 35 / 21 | 9M | 8M |
| Q4 2025 | 104 | 40M | 70.0% | 27 / 38 | 24 / 12 | 10M | 9M |
| Q3 2025 | 91 | 39M | 67.5% | 21 / 28 | 23 / 24 | 5M | 5M |
| Q2 2025 | 94 | 39M | 67.4% | 37 / 27 | 16 / 27 | 4M | 6M |
| Q1 2025 | 84 | 41M | 70.9% | 14 / 19 | 28 / 16 | 2M | 9M |
| Q4 2024 | 87 | 48M | 83.4% | 20 / 34 | 17 / 28 | 5M | 6M |
| Q3 2024 | 96 | 49M | 84.8% | 23 / 37 | 21 / 16 | 12M | 7M |
| Q2 2024 | 90 | 47M | 81.4% | 31 / 25 | 19 / 27 | 15M | 8M |
| Q1 2024 | 88 | 40M | 68.9% | 26 / 24 | 22 / 14 | 7M | 7M |
| Q4 2023 | 76 | 39M | 67.8% | 18 / 24 | 17 / 13 | 7M | 4M |
| Q3 2023 | 73 | 37M | 64.7% | 17 / 23 | 15 / 17 | 5M | 10M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
92 funds held BDTX in Q2 2026, 55% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of BDTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Value Fund, Inc. | 2,119,709 | 3.69% | $3.92M | 0.04% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,556,251 | 2.71% | $2.88M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,209,182 | 2.10% | $2.24M | 0.00% | Jun 30, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 521,043 | 0.91% | $963.93K | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 513,120 | 0.89% | $867.17K | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 511,250 | 0.89% | $945.81K | 0.00% | Jun 30, 2026 |
| iShares U.S. Small-Cap Equity Factor ETF | 469,215 | 0.82% | $792.97K | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 465,655 | 0.81% | $861.46K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Fund | 375,000 | 0.65% | $693.75K | 0.70% | Jun 30, 2026 |
| iShares Biotechnology ETF | 347,116 | 0.60% | $642.16K | 0.01% | Jun 30, 2026 |
| U.S. Small Cap Value Portfolio | 341,219 | 0.59% | $576.66K | 0.00% | Jul 31, 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 248,134 | 0.43% | $459.05K | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 240,495 | 0.42% | $533.90K | 0.00% | May 31, 2026 |
| Dimensional US Small Cap Value ETF | 210,208 | 0.37% | $355.25K | 0.00% | Jul 31, 2026 |
| Small Cap Value Portfolio | 182,571 | 0.32% | $337.76K | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mark A. Velleca | PRESIDENT & CEO, Director | 121,522 | 0.21% | Jan 23, 2026 |
| Brent Hatzis-Schoch | SEE REMARKS | 83,400 | 0.15% | Jan 23, 2026 |
| Sergey Yurasov | CHIEF MEDICAL OFFICER | 75,000 | 0.13% | Jan 23, 2026 |
| Erika Jones | SEE REMARKS | 85,150 | 0.15% | Jan 23, 2026 |
| Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | 170,192 | 0.30% | Jan 23, 2026 |
| Ali Behbahani | Director | 4,558,993 | 7.94% | Sep 21, 2026 |
| Prakash Raman | Director | 51,840 | 0.09% | Sep 21, 2026 |
| Kapil Dhingra | Director | 10,000 | 0.02% | Jun 29, 2026 |
| Samarth Kulkarni | Director | – | – | Jun 29, 2026 |
| Garry E. Menzel | Director | 76,644 | 0.13% | Jun 29, 2026 |
| Shannon Campbell | Director | 8,865 | 0.02% | Jun 29, 2026 |
| Biotech Ag Bb | 10% owner | 8,117,839 | 14.13% | Mar 20, 2025 |
| Growth N. V. Biotech | 10% owner | 3,233,547 | 5.63% | Mar 20, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ali Behbahani Director | Sep 18, 2026 | Award | +7,707 | $1.93 | $14.87K | 110,236 |
| Prakash Raman Director | Sep 18, 2026 | Award | +6,801 | $1.93 | $13.13K | 51,840 |
| Prakash Raman Director | Jun 19, 2026 | Award | +7,907 | $1.66 | $13.13K | 45,039 |
| Ali Behbahani Director | Jun 19, 2026 | Award | +8,961 | $1.66 | $14.88K | 102,529 |
| Prakash Raman Director | Mar 20, 2026 | Award | +6,105 | $2.15 | $13.13K | 37,132 |
| Ali Behbahani Director | Mar 20, 2026 | Award | +6,919 | $2.15 | $14.88K | 93,568 |
| Prakash Raman Director | Dec 12, 2025 | Award | +4,665 | $2.76 | $12.88K | 31,027 |
| Ali Behbahani Director | Dec 12, 2025 | Award | +5,208 | $2.76 | $14.37K | 86,649 |
| Prakash Raman Director | Sep 19, 2025 | Award | +3,843 | $3.35 | $12.87K | 26,362 |
| Ali Behbahani Director | Sep 19, 2025 | Award | +4,291 | $3.35 | $14.37K | 81,441 |
| Prakash Raman Director | Jun 20, 2025 | Award | +5,526 | $2.33 | $12.88K | 22,519 |
| Ali Behbahani Director | Jun 20, 2025 | Award | +6,170 | $2.33 | $14.38K | 77,150 |
| Prakash Raman Director | Mar 21, 2025 | Award | +6,848 | $1.88 | $12.87K | 16,993 |
| Ali Behbahani Director | Mar 21, 2025 | Award | +7,646 | $1.88 | $14.37K | 70,980 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −584,292 | $1.95 | $1.14M | 3,233,547 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −300,000 | $1.94 | $582.00K | 7,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −1,000,000 | $2.31 | $2.31M | 6,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −2,000,000 | $2.00 | $4.00M | 4,217,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −1,000,000 | $2.07 | $2.07M | 7,517,839 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −500,000 | $2.12 | $1.06M | 2,733,547 |
| Growth N. V. Biotech 10% owner | Mar 19, 2025 | Sale | −400,000 | $2.09 | $836.00K | 3,817,839 |
| Erika Jones SEE REMARKS | Jan 30, 2025 | Award | +75,000 | – | – | 85,150 |
| Brent Hatzis-Schoch SEE REMARKS | Jan 30, 2025 | Award | +75,000 | – | – | 83,400 |
| Mark A. Velleca PRESIDENT & CEO, Director | Jan 30, 2025 | Award | +75,000 | – | – | 121,522 |
| Sergey Yurasov CHIEF MEDICAL OFFICER | Jan 30, 2025 | Award | +75,000 | – | – | 75,000 |
| Elizabeth Buck CHIEF SCIENTIFIC OFFICER | Jan 30, 2025 | Award | +75,000 | – | – | 170,192 |
| Shannon Campbell Director | Dec 13, 2024 | Award | +4,500 | $2.50 | $11.25K | 8,865 |
| Prakash Raman Director | Dec 13, 2024 | Award | +5,150 | $2.50 | $12.88K | 10,145 |
| Ali Behbahani Director | Dec 13, 2024 | Award | +5,750 | $2.50 | $14.38K | 63,334 |
| Shannon Campbell Director | Sep 20, 2024 | Award | +2,354 | $4.78 | $11.25K | 4,365 |
| Prakash Raman Director | Sep 20, 2024 | Award | +2,694 | $4.78 | $12.88K | 4,995 |
| Ali Behbahani Director | Sep 20, 2024 | Award | +3,007 | $4.78 | $14.37K | 57,584 |
| Versant Voyageurs I Parallel, L.P. 10% owner | Aug 28, 2024 | Sale | −221,600 | $6.32 | $1.40M | 3,726,341 |
| Ali Behbahani Director | Jun 21, 2024 | Award | +2,887 | $4.98 | $14.38K | 54,577 |
| Shannon Campbell Director | Jun 21, 2024 | Award | +2,011 | $4.98 | $10.01K | 2,011 |
| Prakash Raman Director | Jun 21, 2024 | Award | +2,301 | $4.98 | $11.46K | 2,301 |
| Ali Behbahani Director | Mar 15, 2024 | Award | +3,166 | $4.54 | $14.37K | 51,690 |
| Wendy L. Dixon Director | Mar 15, 2024 | Award | +3,253 | $4.54 | $14.77K | 38,054 |
| Wendy L. Dixon Director | Dec 15, 2023 | Award | +4,043 | $2.73 | $11.04K | 34,801 |
| Ali Behbahani Director | Dec 15, 2023 | Award | +4,455 | $2.73 | $12.16K | 48,524 |
| Growth N. V. Biotech 10% owner | Oct 17, 2023 | Buy | +400,000 | $2.34 | $936.00K | 8,517,839 |
| Wendy L. Dixon Director | Sep 15, 2023 | Award | +2,986 | $3.60 | $10.75K | 30,758 |
| Ali Behbahani Director | Sep 15, 2023 | Award | +3,299 | $3.60 | $11.88K | 44,069 |
| Mark A. Velleca PRESIDENT & CEO, Director | Sep 15, 2023 | Award | +5,208 | $3.60 | $18.75K | 46,522 |
| Ra Capital Management, L.P. Director | Jul 5, 2023 | Buy | +935,850 | $5.00 | $4.68M | 3,213,828 |
| Ali Behbahani Director | Jul 5, 2023 | Buy | +1,000,000 | $5.00 | $5.00M | 4,448,757 |
| Biotech Ag Bb 10% owner | Jun 30, 2023 | Buy | +1,000,000 | $5.00 | $5.00M | 8,117,839 |
| Growth N. V. Biotech 10% owner | Jun 27, 2023 | Buy | +1,740,000 | $5.49 | $9.55M | 7,117,839 |
| David M. Epstein SEE REMARKS, Director | Jun 27, 2023 | Sale(10b5-1 plan) | −25,000 | $6.70 | $167.50K | 671,423 |
| Mark A. Velleca Director | Jun 16, 2023 | Award | +8,929 | $2.10 | $18.75K | 41,314 |
| Ali Behbahani Director | Jun 16, 2023 | Award | +5,655 | $2.10 | $11.88K | 40,770 |
| Wendy L. Dixon Director | Jun 16, 2023 | Award | +5,119 | $2.10 | $10.75K | 27,772 |
| Mark A. Velleca Director | Mar 16, 2023 | Award | +11,228 | $1.67 | $18.75K | 32,385 |
| Wendy L. Dixon Director | Mar 16, 2023 | Award | +6,437 | $1.67 | $10.75K | 22,653 |
| Ali Behbahani Director | Mar 16, 2023 | Award | +7,111 | $1.67 | $11.88K | 35,115 |
| Erika Jones SEE REMARKS | Feb 13, 2023 | Award | +5,075 | – | – | 10,150 |
| Fang Ni SEE REMARKS | Dec 22, 2022 | Buy | +36,363 | $1.28 | $46.54K | 125,389 |
| Fang Ni SEE REMARKS | Dec 21, 2022 | Buy | +20,000 | $1.29 | $25.80K | 89,026 |
| Wendy L. Dixon Director | Dec 16, 2022 | Award | +7,167 | $1.50 | $10.75K | 16,216 |
| Ali Behbahani Director | Dec 16, 2022 | Award | +7,917 | $1.50 | $11.88K | 28,004 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
9.78%
5M shares short
Days to cover
4.9
At 1M shares a day
Change since last report
+2.1%
From 5M shares
Short volume, 20 days
65.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Black Diamond Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,900 shares on Sep 21, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| David Epstein Former Employer | Jul 31, 2024 | 50,000 | $310.00K | Jul 31, 2024 | Founder Shares |
| David Epstein Former Employee | Jul 26, 2024 | 50,000 | $310.00K | Jul 26, 2024 | Founder Shares |
| David Epstein Former Employer | Jul 16, 2024 | 50,000 | $312.50K | Jul 16, 2024 | Founder Shares |
| David Epstein Former Employer | Jul 11, 2024 | 69,024 | $345.12K | Jul 11, 2024 | Founder Shares |
| David Esptein Former Employee | Jul 9, 2024 | 75,000 | $360.00K | Jul 9, 2024 | Founder Shares |
| David Epstein Former Employer | Jun 28, 2024 | 50,000 | $250.00K | Jun 28, 2024 | Founder Shares |
| David Epstein Former Board Member | Jun 27, 2024 | 40,353 | $189.66K | Jun 27, 2024 | Founder Shares |
| David Epstein Former Board Member | Jun 26, 2024 | 9,647 | $45.34K | Jun 26, 2024 | Founders Shares |
| David Epstein Former Board Member | Jun 24, 2024 | 6,011 | $30.18K | Jun 24, 2024 | Founders Shares |
| David Epstein Former Board Member | Jun 21, 2024 | 743 | $3.72K | Jun 21, 2024 | Founders Shares |
| David Epstein Former board member | Jun 20, 2024 | 20,143 | $101.12K | Jun 20, 2024 | Founder Shares |
| Leah Wu Spouse of former board member | Jun 20, 2024 | 20,268 | $101.75K | Jun 20, 2024 | Founders Shares |
| David Epstein Former Board Member | Jun 18, 2024 | 2,951 | $16.08K | Jun 18, 2024 | Founders Shares |
| David Epstein Former Board Member | Jun 14, 2024 | 24,621 | $148.46K | Jun 14, 2024 | Founders Shares |
| David Epstein Former Board Member | Jun 13, 2024 | 70,853 | $435.75K | Jun 13, 2024 | Founders Shares |
See a number that looks wrong?